bluuebunny/crossref_metadata_2025_split huggingface dataset:
Prognostic significance of beat-to-beat variability of spatial heterogeneity of repolarisation analysed from 5-minute resting electrocardiogram in coronary artery disease
Authors: Perkiomaki J , Rahola J T , Mattila S M , Kiviniemi A M , Ukkola O H , Tulppo M P , Junttila M J , Huikuri H V , Kentta T V 
Published: May 2024

Abstract

Background
Data on the prognostic significance of temporal variability of spatial heterogeneity of electrocardiographic repolarisation in coronary artery disease (CAD) are limited.

Purpose
To evaluate the prognostic value of temporal variability of T-wave morphology analysed from 5-minute resting ECG in CAD.

Methods
The standard deviation (SD) of T-wave morphology dispersion (TMD-SD), the SD of T-wave heterogeneity (TWH-SD), and the SD of total cosine R-to-T (TCRT-SD) were analysed on beat-to-beat basis from a 5-minute period of resting 12-lead ECG obtained before a clinical stress test in 1702 patients with angiographically verified CAD and well-preserved left ventricular function.

Results
During an average of 8.7±2.2 years of follow-up, 60 (3.5 %) patients experienced sudden cardiac death (SCD) or were resuscitated from a sudden cardiac arrest (SCA), 69 (4.1 %) patients experienced non-sudden cardiac death (NSCD), and 161 (9.5 %) patients died due to non-cardiac death (NCD). TMD-SD was significantly higher in patients who experienced SCD/SCA compared with those without such an event (1.72 ± 2.00 vs. 1.12 ± 1.75, p= 0.01, respectively) and in patients who succumbed to NSCD compared with those without such an event (1.57 ± 1.74 vs. 1.12 ± 1.76, p=0.04, respectively), but did not differ significantly between patients who experienced NCD and those without such an event (1.16 ± 1.42 vs. 1.14 ± 1.79, p=0.86, respectively). After adjusting for relevant clinical risk factors in the Cox multivariate hazards model, TMD-SD retained its significant association with the risk of SCD/SCA (HR 1.119, 95 % CIs 1.015–1.233, p=0.024), but not with the risk of NSCD (HR 1.089, 95 % CIs 0.983–1.206, p=0.103).

Conclusion
TMD-SD, representing temporal variability of spatial heterogeneity of electrocardiographic repolarisation, is independently associated with the long-term risk of SCD/SCA in CAD patients with well-preserved left ventricular function.
Real life experience with point by point pulsed field ablation for recurrent ventricular arrhythmias
Authors: Ene E , Nentwich K , Berkowitz A , Deaconu A , Deneke T 
Published: May 2024

Abstract

Introduction
The safety and effectiveness of electroporation/point by point pulsed field ablation (PP PFA) as emerging technoloy for catheter ablation (CA) of ventricular arrhythmias (VAs) has been described till now only in case reports.

Purpose
The aim of this observational retrospective study is to present real life data concerning the overall performance of PP PFA for CA of recurrent VA.

Methods
A total number of 13 consecutive patients (11 VTs and 2 PVCs), in whom recurrent VTs after RF ablation documented, were included. In all patients the substrate location was documented beforehand based on cardiac MRI or CT with myocardial thinning. For substrate mapping a high resolution multipoint mapping catheter was used. A complete success was defined as non inducibility of any arrhythmia at the end of procedure respectively lack of VA recurrence at follow – up.

Results
Excepting 2 patients, all other had a non ischemic cardiomyopathy as underlying heart disease (mean age 63 ± 8 y/o, mean LVEF 42 % ± 9 %). In every patient at least one conventional RF CA has been performed previously (mean 2 ± 1) and 38 % of patients had a previous epicardial RF VT ablation. The PP PFA VT ablation was performed endocardialy in 11 patients (84 %), respectively epicardialy in 2 patients. The ablation sites had a septal location in 53 % of patients and other localisation in 47 % of patients. The applied energy was 25 A. The overall acute complete success was achieved in 77 % patients. At medium 6 ± 3 months follow up a complete success was present in 46 % cases. Most frequently a VT recurrence after PP PFA ablation was encountered in patients with combined septal and nonseptal substrate distrubution. After PP PFA, the RF CA strategy due to recurrent VAs was endocardial in 2 patients, respectively epicardial 2 in cases and bipolar in 1 case. No PP PFA redos were undergone. Three major complications have been documented (1 tamponade, 1 AV block III° and 1 complete LBBB).

Conclusion
As bailout strategy in patients with failed conventional CA, PP PFA represents a safe strategy. Specific complications like temporary atrioventricular or intraventricular conduction disturbancies are extremely rare, reversible but not life threathening. The midterm success is satisfactory but still limited in patients with intramural substrate.
Hybrid therapy with ablation + subcutaneous ICD for secondary prevention of sudden cardiac death in ischemic heart disease
Authors: Maury P , Goldenberg I , Huang D , Aktas M , Sacher F , Clementy N , Mulpuru S , Friedman P , Meyer C , Tiefenbrun N , Mcnitt S , Zareba W , Nof E 
Published: May 2024

Abstract

Background
The aim of the prospective Ventricular Tachycardia Ablation- Subcutaneous ICD (VTAbl-SICD) Trial was to provide data on the efficacy and safety of a novel hybrid management strategy that combines VT ablation (VTAbl) with S-ICD implantation in patients who present with scar-related VT. The rate of appropriate therapy in patients with S-ICD may be a quite fairest surrogate of true residual sudden death (SD) risk compared to transvenous ICD (TV-ICD). More specific data on ischemic heart disease – the prominent cause of VT with the better results of VTAbl – may give arguments for questioning current practices in the future.

Methods
32 patients with post ischemic scar-related sustained VT/VF were included. Patients underwent VTAbl with subsequent (or previous prophylactic n=8) S-ICD implant and were followed for 2-years. We evaluate the occurrence of appropriate and ICD therapies once ablated, as well as cardiovascular (CV) readmissions or death. We also compared to 64 propensity-score matched patients implanted with a secondary prevention TV-ICD (enrolled in the Ranolazine in High-Risk Patients With Implanted Cardioverter-Defibrillators (RAID) trial).

Results
Mean age was 57±12 years (28 males, 87%) (53% hypertension, 31% diabetes and 47% congestive heart failure with NYHA 1.6±1). Mean LVEF was 39±9%.There were no major complications associated with the ablation and implant procedures. Propensity-score matched patients implanted with a secondary prevention TV-ICD displayed similar clinical characteristics.
At 16.5±8.6 months FU, appropriate ICD therapy occurred in 5 patients (15%) in the VTAbl-SICD group, significantly lower compared to the TV-ICD group (34 pts, 53%) (p&lt;0.001). This corresponded to 2-year cumulative probability of 20% vs. 71% in the VTAbl-SICD vs. TV-ICD groups, respectively (log-rank p&lt;0.001; Figure 1) and a significant 83% reduction in the risk of appropriate ICD therapy associated with VTAbl-SICD (HR= 0.17 [95% CI 0.07 - 0.39; p&lt;0.001).
Two of the patients who received appropriate ICD therapy in the VTAbl-SICD group may have had unrecognized transient causes of VT (torsades de pointes or unrecognized ischemia), letting 3 out of 32 (10%) with possible aborted SD caused by VT recurrences. There were no cases of untreated symptomatic VT. The rate of CV readmissions was similar in the VTAbl-SICD (41%) vs. TV-ICD group (44%) (p=0.7), whereas mortality was significantly lower in the VTAbl-SICD- vs.TV-ICD- group (0% vs. 17%, respectively; p&lt;0.001)

Conclusions
Our findings suggest that VT ablation in ischemic heart disease patients allow reaching a low residual true risk for SD, which should now be evaluated in terms of cost-effectiveness compared to ablation + S-ICD implantation. Concommitant S-ICD implantation seems to be a safe alternative to TV-ICD without ablation.Appropriate ICD therapy-free KM
Renal denervation for the management of refractory ventricular arrhythmias
Authors: Jacinto S , Teixeira A R , Santos H , Portugal G , Valente B , Lousinha A , Cunha P , Cacela D , Morais L , Santana A , Oliveira E , Ferreira R , Martins Oliveira M 
Published: May 2024

Abstract

Background
While catheter ablation (CA) has proven effective in managing ventricular arrhythmias (VA) associated with structural heart disease, a portion of patients continue to experience refractory VA despite medical treatment and multiple CA procedures. In such cases, additional techniques, such as autonomic neuromodulation, have been explored. Renal denervation (RDN), traditionally performed for the treatment of resistant arterial hypertension, inhibits the afferent renal sympathetic pathway, leading to reduced efferent sympathetic overactivation on a systemic level. Due to this mechanism, it has also been studied for the management of arrhythmias, including atrial fibrillation and VA, with favorable results.

Objective
To assess the effectiveness and safety of RDN for the management of refractory VA storms in high-risk patients.

Methods
A retrospective analysis of RDN procedures for electrical storms, conducted at a tertiary center between February 2020 and September 2023. We analyzed baseline patient characteristics, procedural details, and acute complications. Recurrence of VA after RDN was assessed at one and six months.

Results
A total of 7 patients underwent RDN for the treatment of refractory VA. The mean age was 56 ± 10 years (6 male). The primary diagnosis was ischemic cardiomyopathy (n=5), with a mean left ventricular ejection fraction (LVEF) of 20 ± 5%, and no history of resistant arterial hypertension. All patients had an implantable cardioverter-defibrillator (ICD) (two with concomitant resynchronization therapy). Five patients had undergone previous endocardial VA ablation. Of the two patients without prior VA ablation, one had a contraindication because of a large left ventricle thrombus, and the other was submitted to an electrophysiological study, but without inducible ventricular tachycardia. In the four weeks before RDN, patients exhibited a mean of 12 ± 18 sustained VA episodes, meeting the criteria for electrical storm (3 ≥ episodes in 24h). During the procedure, there was a mean of 7 ± 8 radiofrequency applications in the right renal artery and 6 ± 10 in the left renal artery. No acute complications were observed. One month after the procedure, VA episodes were reduced to a mean of 0 ± 1, with only two patients experiencing recurrent VA. After six months, the absence of VA recurrence remained consistent, with only one patient experiencing new episodes. There were no deaths during this period.

Conclusion
In our pilot study, RDN appeared to be a safe and effective treatment for the management of VA.VA episodes before and after RDN
STereotactic Arrhythmia Radioablation and its place in modern cardiac ElectroPhysiology: Results of an EHRA Survey
Authors: Kovacs B , Lehmann H I , Manninger M , Saguner A M , Futyma P , Duncker D , Chun J 
Published: May 2024

Abstract

Background
Stereotactic arrhythmia radioablation (STAR) is an emerging treatment option for recurrent ventricular tachycardia/fibrillation (VT/VF) in particular in structural heart disease (SHD). However, the current role and envisioned future role of STAR is in clinical practice as viewed by Cardiologists is unknown.

Objective
To assess the current role of STAR, barriers to its use, and expected future role, within the cardiology community.

Methods
An online survey was created with the support of the EHRA Scientific Initiatives committee and distributed via newsletters and social media. The survey consisted of 20 multiple-choice questions with a focus on baseline demographics, awareness / access, current use, and the future role of STAR.

Results
A total of 129 international participants completed the survey, mean age was 43±11 years, 25 (16.4%) were female. Ninety-one (59.9%) participants were cardiac electrophysiologists while 13 (8.6%) were general cardiologists. Nine participants (7%) were unaware of STAR as a therapeutic option. Sixty-four (49.6%) had access to STAR while 62 (48.1%) had treated / referred a patient for treatment. Median number of patients treated was 4 (range 1-100). Common primary indications for STAR were recurrent VT/VF in SDH (45%), recurrent VT/VF without SHD (7.8%) or PVC (3.9%). Based on their knowledge, 49% and 59% of survey participants responded they would consider performing / referring a patient for STAR, respectively. Reported main advantages of STAR were efficacy in the treatment of arrhythmias not amenable to conventional treatment (49%), non-invasive treatment approach with overall low expected acute and short-term procedural risk (23%) and possible higher efficacy than other available treatment options (23%). Survey respondents named one or more previous catheter ablations (CA) or contraindication for CA (79%), diagnosis of SHD (78%), recurrent monomorphic VT with &gt;3 episodes within the preceding 3 months (68%), optimal antiarrhythmic medication (61%) or electrical storm (59%) as prerequisites for the use of STAR. Most respondents foresee a future clinical role for STAR in the treatment of VT/VF with or without underlying SHD (72% and 75%, respectively). Although, only a minority expected a first-line indication for it in with or without SHD (7% and 5%, respectively) and STAR was viewed rather as a bail-out option (48% and 35%, respectively).

Conclusions
STAR is a new option for the treatment of recurrent VT that appears to gain acceptance within the EP community. Randomized-controlled trials and an EHRA consensus document are critical to further define efficacy, patient populations, as well as the appropriate clinical use for the treatment of VT.Central figureFuture role of STAR
Fracture risk analysis of a stylet-driven lead for left bundle branch area pacing using a human beating heart model
Authors: Liu H , Li W , Alleman W , Victorine K , Shaw R 
Published: May 2024

Abstract

Background
Left bundle branch area pacing (LBBAP) has emerged as a promising approach to cardiac physiologic pacing. However, the mechanical stress and fracture risk has not been studied for stylet-driven leads implanted in the left bundle branch area (LBBA).

Purpose
The main purpose of this study was to evaluate the change in curvature during a cardiac cycle when a stylet-driven lead with a rigid distal end was implanted in LBBA and to identify any increased risk of conductor fracture for the LBBAP lead compared to those implanted at the His bundle (HB), traditional right atrium (RA) and right ventricle (RV) locations.

Methods
A high-resolution, four-dimensional human beating heart model was utilized for simulating the stress on the lead. The bending stiffness of lead body segments was measured with 3-pts bending test and the values were assigned to the finite element model. The curvature change of lead body during one cardiac cycle was measured. The safety factor of lead conductors was calculated using the curvature measurements, the conductor’s endurance limit, and the ultimate stress of the material (MP35N). A higher safety factor indicates better lead durability and lower risk of fracture. A parametric study was also performed to investigate how additional implant factors impact the safety factor of LBBAP leads: lead insertion angle, implant depth, degree of slack, and implant location (Figure 1).

Results
A total of 8 implant scenarios for LBBAP were defined and tested using the combination of the implant factors described above. Two RV implanted locations were tested: RV apex and RV apical septum. One HBP and one RA implant location were tested. The region with maximum change in curvature for LBBAP lead was at 0-10 mm proximal to the ring electrode (Figure 2A). The maximum change in curvature on the lead body for LBBAP, HBP, RV, and RA implants were: 0.022±0.005 (n=8), 0.033 (n=1), 0.036±0.002 (n=2), and 0.024 mm-1 (n=1), respectively (Figure 2B). The safety factor for the lead conductors for LBBAP, HBP, RV, and RA implants were 5.57±1.35 (n=8), 3.48 (n=1), 4.62±0.04 (n=2), and 4.65 (n=1), respectively (Figure 2C). The highest safety factor among all implant locations was 7.63, corresponding to a LBBAP implant scenario with mid-septum location, a 45 degree lead insertion angle towards apex, 7.5 mm lead depth in the septum, and low lead slack. HBP had the lowest safety factor among all implant locations.

Conclusion
The stylet-driven lead with a rigid distal end implanted at the left bundle branch area does not introduce any further risk of fracture compared to the HBP or traditional RA/RV implant locations in this computational modeling study.Fig 1: LBBAP implants testedFig 2: Lead curvature and safety factor
Which paced QRS duration can be achieved in selective and non-selective His bundle pacing?
Authors: Foeldvary M , Grigoryan A , Tribunyan S , Bachour C , Feldmann T , Israel C 
Published: May 2024

Abstract

Background
The paced QRS duration (pQRS) is associated with the risk of developing a pacing-induced cardiomyopathy. His bundle pacing (HBP), either selective (sHBP) or non-selective (nsHBP) can achieve a rather narrow pQRSd in patients with a narrow intrinsic QRS (iQRS) or right bundle branch block (RBBB). We prospectively analyzed the pQRS in sHBP and nsHBP and correlated it with the iQRS.

Patients and Methods
All consecutive patients who received an implantation with sHBP or nsHBP were enrolled and received a 12-lead ECG before and after implantation (digital recording, 25 mm/s). Measurements of the pQRS after implantation were performed in unipolar VVI 100 bpm mode to exclude fusion beats. QRS duration was measured in 6fold magnification of the digital ECG (600%) 1) for the iQRS, 2) from the beginning to the end of the QRS in sHBP, 3) from the end of the pacing artifact to the end of the QRS in nsHBP, and 4) from the end of the pseudo-delta wave to the end of the QRS in nsHBP (see Fig.).

Results
In 388 patients (78±11 years, 38% female, 18% RBBB, 9% left bundle branch block) with an iQRS of 110±28 ms before implantation, sHBP was achieved in 206 patients (53%), nsHBP in 182 (47%). In sHBP, the pQRS was 88±18 ms, in nsHBP 123±18 ms including the pseudo-delta wave, 83±14 ms excluding the pseudo delta-wave. In sHBP, the pQRS was on average 15 ms shorter than the iQRS. In nsHBP, the pQRS was 9 ms longer than the iQRS when the pseudo-delta wave was included, and 31 ms shorter if it was excluded, the latter mostly due to correction of a RBBB by nsHBP.

Conclusions
In sHBP and nsHBP, very narrow pQRS durations of 80-90 ms can be achieved. The pQRS is frequently shorter than the iQRS, mostly by correction of a RBBB.QRS measurements in sHBP and nsHBP
Temporal evolution of His bundle pacing thresholds: a sub-study of the PACE-CONDUCT trial
Authors: Buia V , Stangl D , Walascheck J , Rittger H , Vitali-Serdoz L , Bastian D 
Published: May 2024

Abstract

Background
His bundle pacing (HBP) has become a valuable alternative for cardiac resynchronization therapy, offering physiological pacing. This substudy of the PACE-CONDUCT trial aimed to explore the influence selective and non-selective HBP on threshold height. We assessed these parameters in patients with both normal conduction and bundle branch block conduction.

Methods
Our study included 61 consecutive patients with a median age of 73 years, who underwent a successful HBP implantation for indications such as sick sinus syndrome, AV Block 2 type 2, binodal disease, and ablate and pace therapy prior to AV-node ablation. Among these patients, 18 exhibited QRS durations exceeding 150 ms, indicating a complete and broad bundle branch block which made them candidates for cardiac resynchronization therapy (CRT). All patients received HBP implantation with the assistance of a 3D electroanatomical system. This system allowed for low-fluoroscopic, atraumatic evaluation of the His bundle (HB) area, presenting the His voltage as a color-coded map for precise electrode placement.

Results
The feasibility of bundle branch correction is generally accepted in selective HBP distal to the site of block, albeit associated with higher threshold values and potentially lower battery duration. Our analysis encompassed 61 patients who underwent HBP implantation, with 23 patients (37,7%) exhibiting selective HBP and 38 (62,3%) non-selective HBP. Remarkably, 10 out of the 23 patients with selective HBP demonstrated a complete bundle branch block correction after HBP implantation even with a basal QRS durations exceeding 150 ms. We evaluated HBP thresholds at implantation, one day post-implantation, and one month post-implantation, correlating these data with selective and non-selective HBP. Threshold values were converted to volts per millisecond (volts × milliseconds) for analysis. Statistical analysis conducted with IBM SPSS 29.0 revealed a significant difference at the day of implantation, indicating higher threshold capture in selective HBP compared to non-selective HBP (one-sided p-value: &lt; 0.01, two sided p value 0.01). However, this difference could not be sustained at the one-day and one-month threshold follow-ups, suggesting normalization of the selective HBP threshold.

Conclusion
In our study, the initially higher threshold in selective HBP normalized within 24 hours compared to non-selective HBP. Additionally, our study demonstrated the feasibility of selective His pacing in patients with complete bundle branch block and broad QRS durations. These findings provide insights into HBP optimization and encourage further investigations with larger patient cohorts to validate our observations and enhance patient care in the realm of cardiac pacing.Threshold trend
Implantable Loop Recorders in patients with Brugada Syndrome: the BruLoop Study
Authors: Bergonti M , Sacher F S , Arbelo E A , Crott L , Sabbag A S , Casella M C , Saenen J S , Sfondrini I S , De Asmundis C D A , Brugada J B , Tondo C T , Schwarz P S , Haissaguerre M G , Auricchio A A , Conte G C 
Published: May 2024

Abstract

Aims
Available data on continuous rhythm monitoring by implantable loop recorders (ILRs) in patients with Brugada syndrome (BrS) are scarce. Aim of this multicentre study was to evaluate the diagnostic yield and clinical implication of a continuous rhythm monitoring strategy by ILRs in a large cohort of BrS patients, and to assess the precise arrhythmic cause of syncopal episodes.

Methods and Results
A total of 370 patients with BrS and ILRs (mean age 43.5±15.9, 33.8% females) from 18 international centers were included. Overall, 274 (74.1%) were implanted due to symptoms (69.3% syncope, 30.7% palpitations). Over a median follow-up of 3 years, an arrhythmic event was recorded in 30.7% of symptomatic patients (18.6% atrial arrhythmias (AAs); 10.2% bradyarrhythmias (BAs) and 7.3% ventricular arrhythmias (VAs)). In patients with recurrent syncope, the etiology was arrhythmic in 22.4% (59.3% BAs, 25.0% VAs and 15.6% AAs). The ILR led to drug therapy initiation in 11.4%, ablation procedure in 10.9%, implantation of PM in 2.5% and ICD in 8%. At multivariate analysis, the presence of symptoms (HR 2.5, p=0.001) and age &gt;50 years (HR 1.7, p=0.016) were independent predictors of arrhythmic events, while inducibility of VF at EP study (HR 9.0, p&lt;0.001) was predictor of ventricular arrhythmias.

Conclusion
ILR detects arrhythmic events in nearly 30% of symptomatic BrS patients, leading to an appropriate therapy in 70% of them. The most commonly detected arrhythmias are AAs and BAs, while VAs are detected only in 7% of cases. Symptom status can be used to guide ILR implantation.General ResultsArrhythmias